Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 183-194

  Kim, Hye Jin ^a   Park, Jong Wan ^a   Cho, Young Suk ^b   Cho, Chung Hyun ^a   Kim, Ji Seon ^a   Shin, Hyun Woo ^a   Chung, Doo Hyun ^a   Kim, Sang Jeong ^a   Chun, Yang Sook ^a  

^a Seoul National University   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

Author keywords

Cytokines; EMT; HIF 1 ; Inflammation; LPS; Prostatic hyperplasia

Indexed keywords

ASCORBIC ACID; CURCUMIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR TWIST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; RAT;

ANIMALS; CELL LINE; CYTOKINES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MACROPHAGES; MALE; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

RATTUS;

EID: 84868598698     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.09.002     Document Type: Article

References (48)

1. McVary K.T. BPH: epidemiology and comorbidities. Am. J. Manag. Care 2006, 12:S122-S128.
2. Roehrborn C.G. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 2008, 20:S11-S18.
3. Rittmaster R.S. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:389-402.
4. Weisser H., Tunn S., Debus M., Krieq M. 5Alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia. Steroids 1994, 59:616-620.
5. Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1 is mediated by an O-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7987-7992.
6. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
7. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
8. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001, 20:5197-5206.
9. Epstein A.R., Gleadle J.M., Mcneill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., Hamilton D.L., Jaakkola P., Barstead R., Hodgkin J., Maxwell P.H., Pugh C.W., Schofield C.J., Ratcliffe P.J. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
10. Westra J., Brouwer E., Bos R., Posthumus M.D., Meer B.D., Kallenberg C.G., Limburg P.C. Regulation of cytokine-induced HIF-1 expression in rheumatoid synovial fibroblasts. Ann. N. Y. Acad. Sci. 2007, 1108:340-348.
11. Semenza G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 2004, 19:176-182.
12. Yang M.H., Wu M.Z., Chiou S.H., Chen P.M., Chang S.Y., Liu C.J., Teng S.C., Wu K.J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10:295-305.
13. Park S.E., Park J.W., Cho Y.S., Ryu J.H., Paick J.S., Chun Y.S. HIF-1α promotes survival of prostate cells at a high zinc environment. Prostate 2007, 67:1514-1523.
14. Yun Y.J., Li S.H., Cho Y.S., Park J.W., Chun Y.S. Survivin mediates prostate cell protection by HIF-1alpha against zinc toxicity. Prostate 2010, 70:1179-1188.
15. Li S.H., Ryu J.H., Park S.E., Cho Y.S., Park J.W., Lee W.J., Chun Y.S. Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1α. J. Nutr. Biochem. 2010, 21:801-808.
16. Shibata Y., Ito K., Suzuki K., Nakano K., Fukabori Y., Suzuki R., Kawabe Y., Honma S., Yamanaka H. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000, 42:45-55.
17. Roberts R.O., Jacobson D.J., Rhodes T., Klee G.G., Leiber M.M., Jacobsen S.J. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004, 61:124-131.
18. Odunjo E.O., Elebute E.A. Chronic prostatitis in benign prostatic hyperplasia. Br. J. Urol. 1971, 43:333-337.
19. Kohnen P.W., Drach G.W. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J. Urol. 1979, 121:755-760.
20. Nickel J.C., Downey J., Young I., Boaq S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999, 84:976-981.
21. Bouraoui Y., Ricote M., García-Tuñón I., Rodriquez-Berriquete G., Touffehi M., Rais N.B., Fraile B., Paniagua R., Oueslati R., Royuela M. Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detect. Prev. 2008, 32:23-32.
22. Steiner G.E., Newman M.E., Paikl D., Stix U., Memaran-Daqda N., Lee C., Marberger M.J. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182.
23. Royuela M., de Miquel M.P., Ruiz A., Fraile B., Arenas M.I., Romo E., Paniaqua R. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur. Cytokine Netw. 2000, 11:119-127.
24. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 2003, 95:516-525.
25. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995, 270:1230-1237.
26. Zeisberq M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
27. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003, 349:366-381.
28. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 2012, 33:207-214.
29. Robert G., Descazeaud A., Nicolaïew N., Terry S., Sirab N., Vacherot F., Maillé P., Allory Y., de la Taille A. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009, 69:1774-1780.
30. Di Silverio F., Gentile V., De Matteis A., Mariotti G., Giuseppe V., Luiqi P.A., Sciarra A. Distribution of inflammation, pre-malignant lesions incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur. Urol. 2003, 43:164-175.
31. Irani J., Levillain P., Goujon J.M., Bon D., Doré B., Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J. Urol. 1997, 157:1301-1303.
32. Sciarra A., Mariotti G., Salciccia S., Gomez A.A., Monti S., Toscano V., Di Silverio F. Prostate growth and inflammation. J. Steroid Biochem. Mol. Biol. 2008, 108:254-260.
33. Galli R., Starace D., Busà R., Angelini D.F., Paone A., De Cesaris P., Filippini A., Sette C., Battistini L., Ziparo E., Riccioli A. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J. Immunol. 2010, 184:6658-6669.
34. Gatti G., Quintar A.A., Andreani V., Nicola J.P., Maldonado C.A., Masini-Repiso A.M., Rivero V.E., Maccioni M. Expression of Toll-like receptor 4 n the prostate gland and its association with the severity of prostate cancer. Prostate 2009, 69:1387-1397.
35. König J.E., Senge T., Allhoff E.P., König W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004, 58:121-129.
36. Kramer G., Mittereqqer D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur. Urol. 2007, 51:1202-1216.
37. Batlle E., Sancho E., Francí C., Domínguez D., Monfar M., Baulida J., García De Herreros A. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000, 2:84-89.
38. Cano A., Pérez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., Nieto M.A. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2:76-83.
39. López-Novoa J.M., Nieto M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 2009, 1:303-314.
40. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 2009, 119:1417-1419.
41. Slabáková E., Pernicová Z., Slavíčková E., Staršíchová A., Kozubík A., Souček K. TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug. Prostate 2011, 71:1332-1343.
42. Alonso-Maqdalena P., Brössner C., Reiner A., Chenq G., Sugiyama N., Warner M., Gustafsson J.A. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2859-2863.
43. Xie L., Law B.K., Chytil A.M., Brown K.A., Aakre M.E., Moses H.L. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004, 6:603-610.
44. Santibañez J.F. JNK mediates TGF-beta1-induced epithelial mesenchymal transdifferentiation of mouse transformed keratinocytes. FEBS Lett. 2006, 580:5385-5391.
45. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., Klemm F., Pukrop T., Binder C., Balkwill F.R. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 2005, 175:1197-1205.
46. Strippoli R., Benedicto I., Foronda M., Perez-Lozano M.L., Sánchez-Perales S., López-Cabrera M., Del Pozo M.A. p38 maintains E-cadherin expression by modulating TAK1-NF-κB during epithelial-to-mesenchymal transition. J. Cell Sci. 2010, 123:4321-4331.
47. Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B., Saito Y., Johnson R.S., Kretzler M., Cohen C.D., Eckardt K.U., Iwano M., Haase V.H. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 2007, 117:3810-3820.
48. Huang C.H., Yang W.H., Chang S.Y., Tai S.K., Tzeng C.H., Kao J.Y., Yang M.H. Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. Neoplasia 2009, 11:1371-1382.